Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of major depression, generalized or social anxiety disorder, and panic disorder. Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation.
- Mechanism
- Curator reviewed · 7 references
The exact mechanism of action of venlafaxine in the treatment of various psychiatric conditions has not been fully elucidated; however, it is understood that venlafaxine and its active metabolite O-desmethylvenlafaxine (ODV) potently and selectively inhibits the reuptake of both serotonin and norepinephrine at the presynaptic terminal. This results in increased levels of neurotransmitters available at the synapse that can stimulate postsynaptic receptors. It is suggested that venlafaxine has a 30-fold selectivity for serotonin compared to norepinephrine: venlafaxine initially inhibits serotonin reuptake at low doses, and with higher doses, it inhibits norepinephrine reuptake in addition to serotonin. Venlafaxine and ODV are also weak inhibitors of dopamine reuptake.
- Primary indication
- Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.Curator reviewed · 7 structured indications
- Formula / weight
- C17H27NO2 · 277.4018 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1993
- Brand names
Resolves to
PNVNVHUZROJLTJ-UHFFFAOYSA-NSMILESCOC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Venlafaxine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account